Apples to Oranges: Why Peptides and AAS Aren't Direct Competitors

The Wrong Question Everyone Asks

"Are peptides as good as steroids?" comes up constantly in lifting communities, and it's hard to answer as asked. Anabolic-androgenic steroids (AAS) and the peptides most often compared to them don't do the same job, and they don't have the same kind of evidence behind them.

AAS such as testosterone bind the androgen receptor directly, in muscle and in almost every other tissue, and their effect on muscle has been measured in randomized human trials. The peptides in these comparisons work less directly. Growth hormone secretagogues (GHS) like ipamorelin and CJC-1295 prompt the pituitary to release more of the body's own growth hormone. BPC-157 and TB-500 are used for injury recovery, mostly on the strength of rodent and cell studies.

So a fair comparison asks what each compound does and how well that has been shown in people. For the broader picture, see our overview of peptides versus AAS.

The Hypertrophy Debate: GHS vs. Testosterone

For muscle mass and strength, testosterone has far stronger human evidence. The best-known trial is Bhasin and colleagues' 1996 study in the New England Journal of Medicine. It randomly assigned 43 healthy men to placebo or 600 mg of testosterone enanthate per week for 10 weeks, with or without weight training. Men given testosterone without exercise still gained arm and leg muscle area, and added about 9 kg to their bench press and 16 kg to their squat. Men who got testosterone and trained gained about 6.1 kg of fat-free mass, with bench press up about 22 kg and squat capacity up about 38 kg. The dose was well above medical replacement levels and the trial was small and short, but it is a controlled human result.

Nothing comparable exists for GHS stacks. CJC-1295 has been tested in healthy adults only for its effect on hormone levels. In two small 2006 trials, a single subcutaneous injection raised growth hormone 2- to 10-fold for six days or more, and IGF-1 1.5- to 3-fold for 9-11 days. Ipamorelin's human data come from an IV dosing study and a Phase 2 trial in patients recovering from bowel surgery. That trial missed its primary endpoint, according to FDA's 2024 advisory committee review: median time to first tolerated meal was 25.3 hours with ipamorelin vs. 32.6 hours with placebo, not a significant difference. No published trial has measured muscle or strength in lifters using either peptide. Figures like "5-8 pounds of lean tissue in three months" circulate in forums and vendor material, but we couldn't trace them to a study.

The closest human evidence comes from growth hormone itself. In a 2010 randomized trial in 96 recreational athletes, 2 mg/day of injected growth hormone for 8 weeks reduced fat mass and raised lean body mass, but the lean-mass gain came from extracellular water. Strength (deadlift), jump power and endurance didn't change significantly. Sprint capacity rose about 4%, and that gain was gone six weeks after stopping. A secretagogue works through the body's own release, which stays under feedback control, so there's little reason to expect a bigger effect on muscle than injected growth hormone produced.

Users on peptide forums still give reasons for picking GHS over AAS:

1. A different side-effect profile. GHS don't act on the androgen receptor, so they don't carry the testosterone-specific problems: shutdown of the body's own testosterone production, estrogen-related effects from aromatization, acne or hair loss. That doesn't make them free of side effects. A 2018 review of human GHS studies found them generally well tolerated but noted rises in blood glucose from reduced insulin sensitivity. In the ipamorelin Phase 2, the treatment group had more low potassium, high blood sugar and insomnia than placebo. Users commonly report water retention, tingling hands and flushing, and intense hunger with GHRP-6.
2. Use alongside AAS. Some users add GHS to a steroid cycle, hoping for fat loss and better recovery. In the 2010 trial, growth hormone plus testosterone raised sprint capacity by about 8% in men, more than growth hormone alone. That study used injected growth hormone, not a secretagogue.

Forum claims that muscle added on peptides is "drier" or "more permanent" than muscle added on steroids don't fit the growth hormone data above, where much of the lean-mass increase was water.

Healing and Recovery: What the Evidence Shows

This is where peptide advocates make their strongest claims, and where the gap between animal and human data is widest.

Older lifters often suggest low-dose nandrolone (Deca) for sore joints. That reputation rests mostly on anecdote; we didn't find a controlled human trial of nandrolone for tendon or joint pain. It also brings the usual AAS drawbacks, including suppressed natural testosterone and a long detection window in drug testing.

BPC-157 is a pentadecapeptide (15 amino acids) derived from a protein found in gastric juice. In rats, it has sped up healing of tendon, ligament and muscle injuries. In a 2003 study of rats with a cut Achilles tendon, daily BPC-157 injections into the abdominal cavity improved tendon strength, walking function and collagen formation over 14 days compared with saline. Researchers link these effects partly to angiogenesis (new blood vessel growth) and to growth-factor signaling.

The human picture is much thinner. A 2025 systematic review in HSS Journal found 36 studies of BPC-157 for musculoskeletal injury: 35 were preclinical and one was clinical, a small knee-pain series in which 7 of 12 people reported relief lasting more than six months. The authors found no clinical safety data. A 2025 IV pilot in two adults reported no side effects and no changes in blood markers at 10 and 20 mg. As of October 2026, no controlled human trial of BPC-157 has published results. Users commonly report 250-500 mcg per day by subcutaneous injection, often near the injury, though no human trial has compared injection sites. User reports are mixed: some describe clear improvement within weeks, while others notice nothing after a month or more. Variable gray-market product quality may explain part of the gap, and rat results don't always carry over to people.

TB-500 is often called synthetic thymosin beta-4, but that isn't accurate. TB-500 is a 7-amino-acid fragment (Ac-LKKTETQ) of the 43-amino-acid protein. Full thymosin beta-4 binds actin, a protein cells need in order to move, and has been studied for wound and eye repair. As of October 2026, FDA says it has found no human exposure data for the TB-500 fragment. The human trials that exist used the full protein, and the results are mixed. The ARISE-3 Phase 3 trial of thymosin beta-4 eye drops for dry eye missed its primary outcome measures in 2021, though it improved one secondary symptom. A second Phase 3 eye-drop trial (SEER-2, in a corneal disease) was still listed as recruiting at its last registry update. None of this tells us what an injected fragment does for a tendon.

Steroids raise protein synthesis throughout the body, but whether they speed healing of a specific injured tendon in people hasn't been well tested either. Neither class has strong human data for connective-tissue repair, and the peptide case rests almost entirely on animal studies.

A Realistic Head-to-Head Comparison

The table compares testosterone with the two peptide groups above, based on what has been shown in people.

AAS users commonly follow a cycle with post-cycle therapy (PCT) to help restart natural testosterone production. GHS don't suppress testosterone, so PCT isn't needed for that reason, but the long-term effects of GHS use haven't been studied. Our article on long-term effects of peptides versus steroids covers what is known. The AAS side-effect list is also longer than the table shows: a 2014 Endocrine Society scientific statement links performance-enhancing drug use to a higher risk of death and to cardiovascular, psychiatric, liver and endocrine disorders.

What we still don't know

• No trial has compared any peptide with AAS head-to-head for muscle, strength or injury recovery.
• No published trial has measured muscle gain or strength in healthy lifters using CJC-1295, ipamorelin or GHRP-6.
• BPC-157's rodent results haven't been tested in a controlled human trial, and nobody knows what an effective human dose would be.
• The TB-500 fragment has no human data at all, and users often can't tell whether a vial sold as "TB-500" holds the fragment or full thymosin beta-4.
• Regulation is still moving. As of October 2026, none of these peptides is approved as a drug, and FDA advisers voted in July 2026 to add BPC-157 and TB-500 to the 503A compounding list, but FDA hasn't acted on that vote. Our guide to legal frameworks for peptide use covers the details, and our page on peptide cycling strategies describes the on/off schedules users report.